Skip to content

Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry

Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07538622
Enrollment
300
Registered
2026-04-20
Start date
2026-07-29
Completion date
2028-09-01
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPH (Benign Prostatic Hyperplasia)

Keywords

Benign Prostatic Hyperplasia (BPH), Symptomatic BPH, BPH, Benign Prostatic Hyperplasia, enlarged prostate, lower urinary tract symptoms (LUTS), LUTS

Brief summary

The purpose of this registry is to collect information on how the Zenflow Spring System works in everyday medical practice. The registry will track how the Spring System performs during the implant procedure, and at follow-up visits at 1, 3, 6, and 12 months. We will look at how symptoms improve, how quickly patients return to normal activities, how satisfied they are with treatment, and whether there are any problems or side effects related to the device.

Interventions

Minimally Invasive Treatment for LUTS associated with BPH

Sponsors

Zenflow, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Treatment with Zenflow Spring System will be conducted in accordance with the approved Instructions for Use

Exclusion criteria

* Treatment with Zenflow Spring System will be conducted in accordance with the approved Instructions for Use

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness - IPSSBaseline to 12 MonthsThe primary effectiveness endpoint is the change in IPSS from baseline over time
Safety - adverse eventsBaseline to 12 MonthsThe primary safety endpoint is the observed rate of device-related serious adverse events (SAEs)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026